Back to all papers

Individualized treatment effects of corticosteroids in IgA nephropathy

Authors

Hoelscher, D. L.,Schmitz, N. E.,Niggemeier, L.,Pilva, P.,Strauch, M.,Tesar, V.,Barratt, J.,Roberts, I. S.,Coppo, R.,the VALIGA investigators,,Barisoni, L.,the CureGN investigators,,Yanagita, M.,Alabalik, U.,Rule, A. D.,Jagtap, J. M.,Abreu, E. S.,Taal, M. W.,Kalra, P. A.,the NURTuRE academic steering group,,Floege, J.,Kramann, R.,Boor, P.,the AI4IgAN study,,Buelow, R. D.

Affiliations (1)

  • Institute of Pathology & Department of Nephrology and Immunology, RWTH Aachen University Hospital

Abstract

IgA nephropathy (IgAN) is a leading cause of kidney failure with diverse clinical presentations and treatment responses, particularly to corticosteroids, with conflicting evidence. Due to potentially severe side effects and heterogenous responses more individualized approaches are needed. We developed a causal machine learning framework for predicting individualized treatment effects of corticosteroids in IgAN by integrating clinical variables, histopathological scores, and deep learning-based biomarkers from digitized kidney biopsies (pathomics) of 1,022 patients from eight retrospective international cohorts. At the cohort-level, corticosteroids showed no significant effect on five-year kidney survival. However, the framework identified subpopulations with and without significant treatment benefit, improving progression-free kidney survival and also reducing overtreatment in low-benefit patients. Pathomics highlighted tubulointerstitial inflammation and glomerular tuft deformation as predictors of corticosteroid response. Our framework offers a blueprint for precision therapy in IgAN, supporting clinical decision-making in the era of emerging targeted treatments.

Topics

nephrology

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.